HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield reiterates a Buy rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintains a $36 price target.
June 08, 2023 | 10:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reiterates Buy rating on 4D Molecular Therapeutics (FDMT) and maintains a $36 price target.
The reiterated Buy rating and maintained $36 price target by HC Wainwright & Co. analyst Matthew Caufield indicates a positive outlook for 4D Molecular Therapeutics (FDMT) in the short term. This news is directly related to FDMT and is important for investors as it reflects the analyst's confidence in the company's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100